BioTime Licenses Technology for Key Regulatory Gene Underlying Cancer and Stem ... MarketWatch (press release) This may permit the repair or replacement of a patient's damaged tissues and organs without the risk of transplant rejection. BioTime, headquartered in Alameda, California, is a biotechnology company focused on regenerative medicine and blood plasma ... |
